Former FDA officials defended the decision not to approve the cancer drug Replimune, despite intense pressure from the Wall Street Journal's opinion board and investors like BlackRock. The agency cited a lack of substantial evidence and the company's failure to conduct a proper control group study. Allegations surfaced that the media campaign for the drug was a "stock play" rather than a compassionate plea for melanoma patients, as the company's stock has since plummeted.
